

Initiatives to Promote the Healthcare Industry in Malaysia

Abd Ghani Abd Aziz

Principal Assistant Secretary

National Biotechnology Division

Ministry of Science, Technology & Innovation

andonl

FRAMEWORK FOR THE NATIONAL POLICY ON SCIENCE, TECHNOLOGY AND INNOVATION (NPSTI)

A High Income, Inclusive and Sustainable Nation



Transformation Programme





National Social Transformation Programme (NSTP) Political Transformation Programme (PTP)

Vision

Mission

A scientifically advanced nation for socio-economic transformation and inclusive growth

Advancing and mainstreaming STI at all levels and in all sectors

Strategic Thrusts

Foundation

ST 1
Advancing
scientific and
social
research,
development
and
commercialisa
tion

ST 2
Developing,
harnessing
and
intensifying
talent

ST 3 Energising industries

ST 4
Transforming
STI
governance

ST 5
Promoting
and
sensitising
STI

ST 6
Enhancing
strategic
international
alliances

STI for Policy

Policy for STI

Industry Commitment to STI

STI Governance

STI for Stable, Peaceful, Cohesive and Resilient Society






The Malaysian Government commits itself to undertake the role of developer and catalyst of the country's biotechnology sector


BRAND STATEMENT

Biotechnology for wealth creation and social well-being

VISION

Position biotechnology as the new economic engine to enhance prosperity and wellness of the nation by 2020





National Biotechnology Policy







3 PHASE STRATEGIE

PHASE I CAPACITY BUILDING 2005 - 2010

- Provide Biotechnology Development Incentives
- Improve Human Capital & Skills Development
- Improve Job Creation
- Intensify R&D

- Accelerate Development In Agricultural, Healthcare & Industrial Biotechnologies
- Strengthen Legal & IP Framework
- Develop Bioinformatics
- Develop Bionexus Companies

PHASE II SCIENCE TO BUSINESS 2011 - 2015

- Intensify RDI Participation
- Expand Pool of Knowledge Workers
- Develop Expertise In Drug Discovery & Development On Biodiversity & Natural Resources
- Improve New Products Development
- Intensify Technology Acquisition
- Develop Capability In Technology Licensing
- Create Global Brands

PHASE III GLOBAL BUSINESS 2016 - 2020

- Consolidate Strengths & Capabilities In Biotechnology Development
- Intensify Expertise & Strength In Drug Discovery & Development
- Create Leadership In Innovation & Technology Licensing
- Create Greater Value Through Global Malaysian Companies
- Strengthen Branding Of Malaysia As A Global Biotech Hub



BIOTECH CLUSTER CORE BUSINESS

Commercialisation Arms



Facilitating lead agency for Commercialisation and Investment in Biotechnology Industry



Contract Manufacturing Organisation (CMO) specialising in biomanufacturing and biopharmaceuticals



Formulation and Implementation of Biotechnology Policy



Biotechnology Incubator



Integrated Incubator Park with herbal biotechnology facilities providing innovative solutions for industry

Research Arms

NIBM



Agro-biotechnology development



Translational research on genomics and molecular biology



Drugs discovery and development

Pelaksanaan

Dasar Bioteknologi Negara

2005

✓ Dasar Bioteknologi Negara

國名屬

- √ Makmal Interim2007 Bioteknologi
- ✓ BioNexus
- ✓ Bangunan baru ABI, MGI & IPharm
- **✓ ICGEB**
- ✓ Pelaksanaan GLP
- √ biotech@school
- ✓ Kerjasama Malaysia - MIT



2012

- ✓ Pelancaran Program BTP
- ✓ Penubuhan Majlis Bioetika Negara



Fasa I (2005-2010) Pembangunan Kapasiti

2008

- ✓ Bioteknologi mikrograviti
- ✓ Genom Computing Centre (GCC)
- √ biotech@community

2009





R&D ke pasaran

Fasa II (2011-2015)

2013

- √ BioBorneo
- √ National Biotechnology Seminar

2014

- ✓ Pengkorporatan **NIBM**
- √ Bio Accelarat
- ✓ BioShoppe



2020

- ✓ Syarikat bioteknologi bertaraf global
- ✓ BioMalaysia sebagai Hab Global









SCOPE & FLEXIBILITY





3.1 PENYELIDIKAN & PEMBANGUNAN BIOTEKNOLOGI

Pembiayaan Dana R&D Bioteknologi (2011-2015)



Jumlah Keseluruhan RM100 juta



R&D HEALTHCARE BIOTECHNOLOGY



MARDI

Product: Dermaco Tm M7

A novel value added virgin coconut oil based product with broad spectrum of antimicrobial activity against selected pathogenic microorganism

(1 Patent filed)



EntoGeneX Industries Sdn. Bhd.

Product : Biolarvicide Mostique

The production of Trypsin Modulating Oostatic Factor (TMOF), a small mosquito-derived peptide expressed within the *Pichia Pastoris* yeast cells to stops the digestive protein synthesis in larval and adult mosquitoes



SEMI-REFINED CARRAGEENAN

DESCRIPTION



(TF1107B040)

(OMNI-GEL SDN BHD) gankiantee@gmail.com

Upgraded facilities for production of Food Grade Carrageenan from Non-Grade food carrageenan in compliance with GMP requirement and HACCP quality control to produce functional products such as drug delivery capsules and new hydrocolloids.

NOVELTY OF THE PRODUCT

Wide range of usage for production of food additives, binders and emulsifier and functional products

TECHNOFUND



CULTIVATED KACIP FATIMAH PLANTS



(TF0707B004)

PHARMANIAGA BERHAD

DESCRIPTION

Pharmaniaga Berhad has accomplished the research on propagation and cultivation of Kacip Fatimah (*Labisla Pumila var alata*) plants according to Good Agriculture Practice (GAP), Skim Akreditasi Malaysia (SALM) in a old oil palm plantation.

Cultivated Kacip Fatimah will give advantages to ensure sustainable Kacip Fatimah source to meet market demand, preserve wild forest and also to served as corporate social responsibility to small contract farmers.



BIOTECHNOLOGY COMMERCIAL READY PROTOTYPES/ PRODUCTS

STEM CELL REGENERATIVE THERAPHY

Тури	ICRS II	letrasp	18 th Month Pestop – site of biopsy	HAE	Salvanio-O	Cellages I	Collagon II
Normal cortlege	1340	Noi applicable		rai	N.		
Custoil Thoragy	997			1	100	-	
Stem Cell Thoragy	1066					(IN	ğ

(TF0409B104)

(Inno Bio Ventures Sdn Bhd)
www.innobioventures.com

DESCRIPTION

Combination of peripheral blood-derived stem cell (PSC) and hyaluronic acid has a function to regenerate hyaline cartilage. This theraphy has functional outcome of microfracture surgery on damaged knee cartilage.


NOVELTY OF THE PRODUCT

The regeneration of hyaline cartilage with the novel therapy method that comprises of arthroscopic subchondral drilling, postoperative intra-articulsar injections of autologous pheripheral blood stem cells in combination with hyaluronic acid



BIOTECHNOLOGY COMMERCIAL READY PROTOTYPES/ PRODUCTS

TONGKAT ALI HAIRY ROOT



(TF0508B064)

Dr. Nor Hasnida Hassan (FRIM) hasnida@from.gov.my

DESCRIPTION

The Tongkat Ali hairy root culture considered as the best alternative and promising sources for the production of Tongkat Ali biologically active compounds for both commercial and scientific applications as well as to ensure adequate supply for both herbal industries and conservation purposes.

NOVELTY OF THE PRODUCT

Faster production of Tongkat Ali hairy root through bioreactor technology in approximately 3 months as compared to conventional method (5 years).

Patent : P2010003919 (Pending)

Inno Bio

HEALTHCARE





Contracts secured with Indian and Korean companies



"Emerging Company of the Year 2010 "
Award at 2nd BioSpectrum Asia Pacific Awards





Successful humanisation of antibody

- Using the technology licensed from Centre of Molecular Immunology (CIM), IBL has successfully humanised 2 anti cancer antibodies targeted for colorectal cancer.
- •IBL is currently conducting the animal study in mouse.



Strategic partnerships with global companies

- Established partnership with Boehringer Ingelheim, GE Healthcare, Centre of Molecular Immunology (CIM), Cuba and CEVEC GmbH.
- Member of MIT Centre for Biomedical Biomanufacturing Alliance.



Establishment of the FIRST cGMP biomanufacturing facility in Malaysia

- •Biologics manufacturing using recombinant DNA in mammalian cell
- -large-scale production of therapeutic proteins to treat a variety of diseases.



Inno Biologics



The Herbal Biotech Centre, Raub, Pahang





TPM Biotech continues to support the herbal industry by leveraging on its people and facilities. The latest development include HALAL testing and analysis which supports the food and feed industry











The Biotechnology Development Centre, TPM Bukit Jalil, Kuala Lumpur





Malaysian Institute of Pharmaceuticals & Nutraceuticals

THRUST 2 HEALTHCARE BIOTECHNOLOGY DEVELOPMENT



Vision

A centre of excellence for commercializationdriven R&D in healthcare biotechnology

Research Focus:

Discovery of functional food and drug from natural tropical resources for healthcare biotechnology development

Platform:

Bioactive Compunds, Bioprocessing & Advanced Drug Delivery System







Development of Natural Products Library from Malaysian biodiversity for systematic discovery of potential active therapeutic agents for Obesity




504 Plant Species



552 crude extracts

Methanol and Water extract









1000 Partitions




Isolated Compounds









MyNature 50000 comprises a chemical library; extracts, fractions and compounds of local Malaysian plants for research purposes. This library is developed by Natural Product Drug Discovery (NPDC) team under Malaysian Institutes of Pharmaceuticals and Nutraceuticals (IPharm).

Our goal is to create a global resource for natural product. To achieve this purpose, we collaborate in construction of chemical library, validation of biological activities, and determination of target molecules.



A RAPID COST EFFECTIVE APPROACH

CHEAP, EASY, FAST AND REPRODUCIBLE

EASY ACCESS TO A PARTICULAR PLANT CHEMICAL PROFILE AND ACTIVITY

CONVENIENT AND EASY ACCESS TO MALAYSIAN NATURAL PRODUCT

WE PROVIDE SOLUTIONS FOR:



PLANT EXTRACTS
PLANT PARTITIONS
PLANT FRACTIONS
PURE COMPOUNDS

READY FOR SALES



It is our most popular competitively priced collection of 500 plant species

Dried plant species also available in stock

Upon customer request the sample stock also available in DMSO solvent

Price depends on the type, number of extract or compounds selected and a sample size.


1mg samples size in dry form varies from RM35-60



BioMedical within the Bio-Based Industry



Innovations are driving a growing demand for sustainable and bio-based products from renewable bio-based materials




The application of **bio-based technologies is the GAME CHANGER** that transform conventional processes and industries in the bioeconomy into major contributors to the national economy

Bioeconomy Transformation Programme (BTP)



A platform for the private sector to channel and maximise commercial opportunities from bio-based technologies









Benefits of BTP





BTP Trigger Projects are expected to generate impacts on GNI, job creation and investment



Biopharmaceuticals

Stem Cells and Regenerative Medicine

Molecular Screening and Diagnostics

Drug Discovery & Preclinical Services













InnoBio

StemLife

sengenics

GNI in 2020



RM 0.79 bil

Job Opportunities by 2020



2,611

Investment by 2020



RM 1.33 billion





Government Support

National Visibility







Funding Access



Market Access





THANK YOU